论文部分内容阅读
目的探讨保守治疗早期异位妊振的几种方案。方法将88例早期异位妊娠患者,根据不同治疗方案分4组治疗,比较各组治疗效果。结果A组:甲氨蝶呤(MTX)组23例成功(86.4%),其中4例行第2次注射MTX(17.4%);B组:MTX+米非司组22例成功(87.7%),其中4例行第2次注射MTX(18.2%);C组:MTX+中药组24例成功(88%);期待治疗组19例,成功率100%,血β-HCG水平>2000U/L者,第2次用药率高达37%.A,B,C组疗效比较,差异无统计学意义(P>0.05)。结论4种保守治疗方案对早期异位妊娠患者均有效;血β-HCG水平在1000U/L以下且继续下降,包块<3cm者,可在医院密切观察暂不用药。血β-HCG水平>2000U/L者需第2次注射MTX的患者增多。B,C两组较A组明显缩短血β-HCG降至正常所需的时间,减少住院日(P<0.01),B,C两组间没有明显的差异(P>0.05),但C组副反应明显比B组少(P<0.05)。故MTX单次肌内注射联合中药治疗输卵管妊娠疗效好、副反应少,值得临床推广。
Objective To investigate the conservative treatment of early ectopic pregnancy vibration of several programs. Methods 88 patients with early ectopic pregnancy, according to different treatment programs were divided into 4 groups, the treatment effect of each group were compared. Results In group A, 23 cases were successfully treated with methotrexate (MTX) (86.4%), of which 4 cases received the second injection of MTX (17.4%); Group B: MTX + Among them, 24 cases were injected with MTX (18.2%) for the second time; 24 cases (88%) were treated with MTX + TCM in group C; 19 cases were expected to receive treatment with 100% success rate and blood β-HCG level> 2000U / The second medication rate was as high as 37%. There was no significant difference in efficacy between A, B and C groups (P> 0.05). Conclusions Four kinds of conservative treatment regimens are effective in patients with early ectopic pregnancy. Blood β-HCG levels below 1000U / L and continue to decline, mass <3cm, can be closely observed in the hospital temporarily without medication. In patients with blood β-HCG level> 2000U / L, the second injection of MTX increased. Compared with group A, group B and C significantly shortened the time required for the reduction of serum β-HCG to normal, and reduced the length of stay (P <0.01). There was no significant difference between group B and C (P> 0.05) Side effects were significantly less than those in group B (P <0.05). Therefore, a single intramuscular MTX treatment of tubal pregnancy with good efficacy, fewer side effects, it is worth clinical promotion.